Clune & Associates, Ltd. Acumen Pharmaceuticals, Inc. Transaction History
Clune & Associates, Ltd.
- $400 Billion
- Q3 2025
A detailed history of Clune & Associates, Ltd. transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Clune & Associates, Ltd. holds 16,500 shares of ABOS stock, worth $30,030. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,500
Previous 16,500
-0.0%
Holding current value
$30,030
Previous $19.1 Million
47.41%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding ABOS
# of Institutions
73Shares Held
38.1MCall Options Held
31.5KPut Options Held
0-
Ra Capital Management, L.P. Boston, MA14.9MShares$27.2 Million0.38% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$6.22 Million1.28% of portfolio
-
Franklin Resources Inc San Mateo, CA3.08MShares$5.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$3.93 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.95MShares$3.55 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $73.7M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...